Two Major Drugs Pushed Back In One Day - The Return Of A Stricter US FDA?
COVID Vaccines and Alzheimer's Drug Will Be Next Tests
Knock-backs for Gilead/Galapagos and BioMarin are a surprise, and could be a sign of the FDA reasserting its 'gold standard' approach to safety and efficacy.
You may also be interested in...
The year began with an unusually low number of CRLs, but a recent burst of non-approval actions suggests a COVID-19 effect.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.